Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2024

Sep 5, 2024

31100_dirs_2024-09-05_cb787336-146e-478e-94b1-04ceb465ca95.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-09-03

Reporting Person: Eydelman Mikhail (SVP, GEN COUNSEL & CORP SEC)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-09-03 Common Stock M 1667 $21.41 Acquired 32493 Direct
2024-09-03 Common Stock S 4 $107.67 Disposed 32489 Direct
2024-09-03 Common Stock S 523 $110.449 Disposed 31966 Direct
2024-09-03 Common Stock S 715 $111.566 Disposed 31251 Direct
2024-09-03 Common Stock S 122 $112.661 Disposed 31129 Direct
2024-09-03 Common Stock S 79 $114.96 Disposed 31050 Direct
2024-09-03 Common Stock S 144 $116.01 Disposed 30906 Direct
2024-09-03 Common Stock S 80 $117.28 Disposed 30826 Direct
2024-09-03 Common Stock F 2203 $110.15 Disposed 28623 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-09-03 Stock Option (right to buy) $21.41 M 1667 Disposed 2032-05-08 Common Stock (1667) Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $110.12 to $110.76. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $111.16 to $112.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $112.35 to $113.14. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024 were sold by the Reporting Person.

F6: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.